Congenital mesoblastic nephroma (CMN) is a rare pediatric renal tumor with low malignant potential that most commonly occurs early in infancy. Treatment strategies are based on the few published CMN series, while a significant number of CMN patients have been described in case reports. The aim of this narrative review was to create an up-to-date overview of the literature.
INTRODUCTION
Congenital mesoblastic nephroma (CMN) is a rare tumor with low malignant potential, which represents approximately 3% of all pediatric renal tumors. [1] [2] [3] It is the most common renal neoplasm diagnosed in the first month of life. 4, 5 CMN is frequently recognized before or at time of birth, illustrating the embryonal character of the disease. 
METHODS
For this review, databases of PubMed, Embase, Web of Science, Scopus, and Google scholar were searched using search terms "mesoblastic nephroma," "mesoblast" within three words of "nephrom," "non-Wilms" or "not-Wilms" (mesoblastic nephroma* [tw] OR (mesoblast* (Fig 1) . Thirteen articles were added after hand searching. Articles were selected on the basis of title and abstract by two independent reviewers (S.L.G. and T.D.) (Fig 1) . To be eligible for inclusion, a study had to (1) contain well-described CMN patients less than 18 years of age, (2) be an original article, (3) be reported after the study by Bolande et al. (1967) , (4) be written in English language, and (5) be available in full text. In case of doubt about the histologic diagnosis or in case the tumor was described under a different name, the paper was reviewed extensively by an expert pathologist (G.J.V.) before inclusion in the current review.
RESULTS
A total of 200 articles met the inclusion criteria (Fig. 1 ). Of these, 26 articles reported series of 10 patients or more that included 642 patients in total (Table 1 and Supplementary Table S1 ). Where more than one paper reported on the same or overlapping cohorts, the report with the most detailed information on the largest number of individuals was used; eventually 12 nonoverlapping series including 306 patients were selected for the analysis in this review (Table 1 ).
In addition to these series, 174 case reports described 270 cases in total (Supplementary Table S2 ). Data of these case reports were only included in the analysis of this review if they were well documented and provided relevant additional information, such as the correlation between genotype and histology and characteristics of stage III or relapsed CMN patients.
Clinical characteristics
Median age at diagnosis ranged from 0 days (newborn) to 2.9 months (median age ≤1 month in 63% of series) and overall age ranged from prenatal to 3.8 years (Table 1) . Prenatal detection of the tumor was reported in 16% of the patients. 15, [17] [18] [19] The male-to-female ratio was 1.5:1 ( Table 1) . The most commonly reported presenting symptom was an abdominal mass, described in 76% of the cases (Table 1) .
Other repeatedly reported symptoms were hypertension (19%) and hematuria (11%) ( Table 1) . Case reports additionally reported polyhydramnios in 40/270 cases (15%), hypercalcemia in 12/270 cases (4%), and hyperreninemia in 3/270 cases (1%) (Supplementary Table S2 ).
Both hypercalcemia and hyperreninemia completely resolved with the removal of the tumor in all cases. 5, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Congenital anomalies were reported in 11 patients described in series; genitourinary anomalies were described in six patients, gastrointestinal malformations in two patients, polydactyly in one patient, hydrocephalus in one patient, and one patient was described to be diagnosed with Beckwith-Wiedemann syndrome (BWS). 2, 15, 18, 35 In case reports, two additional patients with BWS were diagnosed with CMN. 5, 36 Mean follow-up instead of median follow-up spindle cells and low mitotic activity, no capsule, infiltrative growth into the renal parenchyma and/or perirenal fat, and entrapped islands of parenchyma. 37 The cellular type, identical to infantile fibrosarcoma, shows dense cellularity, a strong hemangiopericytous vascular pattern, and a high mitotic activity but less infiltrative growth into the renal parenchyma. 10, 37 Mixed type CMN shows a mixture of these two patterns in any proportion. 37 Information on histologic subtype was available for 231 patients; the classic type occurred in 91 patients (39%), the cellular type in 96 patients (42%), the mixed type in 23 patients (10%), and classic/mixed type (no discrimination) in 21 patients (9%) ( Table 1) . In three series, a significant difference in age between classic (median age ranging between 6 and 17 days) and cellular type CMN (median age ranging between 3.7 and 5 months) was reported. 15, 16, 19 The median age of mixed type CMN was described in only one series, that is 1.9 months. 16 Information on stage was available for 251 patients; stage I/II disease was found in 208 patients (83%) and stage III disease in 42 patients (17%) ( Table 1) . Reasons for stage III disease were positive surgical margins (n = 13), tumor rupture (n = 12), or a combination of positive surgical margins and tumor rupture (n = 11), while the reason for stage III was unknown in eight patients. 2, 10, [15] [16] [17] [18] [38] [39] [40] One patient was described to have stage IV disease because of "suspected" malignant cells in the bone marrow; however, these cells were not histologically proven to be CMN cells, so we consider this case not being stage IV. 35 In case reports, another case was described to have stage IV disease at diagnosis (lesions in the right tibia on computed tomography scan but no histologic confirmation available). 41 Bilateral (stage V) disease has never been reported. Stage in relation to histologic type is presented in Figure 2 .
Pathology
Data on immunohistochemistry were described in one series,
showing immunoreactive renin (intense staining in vessels within areas of the trapped cortex) in 10/12 studied cases. 38, 39 Case reports provided information on immunohistochemical staining in 53 cases. In these cases, in total 27, different immunohistochemical markers were used. No marker specific for CMN could be identified (Supplementary   Table S3 ).
Genetics
The most commonly reported genetic aberrations in CMN are t(12;15)(p13;q25), leading to a fusion of the genes ETV6 and NTRK3, and trisomy 11 (both somatic). In Table 2 and those harboring trisomy 11 were both 1 month.
Other recurrently reported genetic aberrations in CMN (in case reports) are trisomies 8 (n = 9), 17 (n = 4), 20 (n = 4), 7 (n = 3), 10
(n = 3), 18 (n = 2), 2 (n = 2), and 9 (n = 2) (Supplementary Table S2 );
all identified aberrations only occurred in mixed/cellular type CMN.
Treatment
Treatment details were available for 263 patients. Preoperative chemotherapy was administered in only nine patients, consisting of actinomycin and vincristine (AV) in eight patients and unknown type of treatment in one patient. 15, 16, 18 Information on response to preoperative chemotherapy was described in six cases; five cases treated with AV showed a reduction in tumor size of at least 30% and one case treated with AV had a significant increase in tumor size, but histology at the time of surgery showed 80% necrosis. 15, 16 All patients underwent surgery (179 complete nephrectomy, 6 partial nephrectomy [re-excision n = 3], 77 unknown type of surgery), except for one patient who died before surgery could be applied. 
Outcome
Information on outcome was available for 276 patients described in series (Table 1 ). Of these, 264 patients survived (96%) and 12 patients died (4%). In these 12 patients, the cause of death was disease related in 5 cases and treatment related in 7 cases (5 surgery-related, 2 chemotherapy-related) (Supplementary Table S4 ). Median age at diagnosis of patients who died of disease was 6 months, while median age at diagnosis of patients who died of treatment-related causes was 0 days (newborn). Surgery-related causes of death included postoperative sepsis (n = 2), postoperative necrotizing enterocolitis (n = 1), intraoperative bleeding (n = 1), and "not specified"
(n = 1). Chemotherapy-related causes of death consisted of severe neutropenia and sepsis (n = 2).
Information on occurrence of relapse was available for all 306 patients described in series. Relapses occurred in 12 patients (4%) (9 local, 2 metastatic in lung and bone, and 1 location unknown) (Supplementary Table S5 ). The histologic subtype was known in 11 relapsed cases (8 cellular, 1 classic, and 2 mixed). Information on outcome after relapse was available in 10 cases; 6 patients achieved a second complete remission and 4 patients died of disease (Supplementary Tables S5 and S6 ).
Outcomes of patients harboring t(12;15)(p13;q25) and trisomy 11 are described in Table 2 .
DISCUSSION
The aim of this narrative review was to present a comprehensive and up-to-date overview of clinical characteristics, optimal treatment strategies, and outcome of different histologic and genetic subtypes of CMN, thereby serving future treatment guideline development for this rare tumor.
Most studies reporting on CMN have not been based on (inter-)national registries. Therefore, the prevalence of CMN and its
histologic subtypes is hard to analyze. Large series have suggested that CMN comprises 3.5-4% of all pediatric renal tumors, but it is conceivable that perinatal diagnosed cases may have been considered benign and therefore not have been included in renal tumor registries. 15, 16 The frequency of the cellular subtype and classic subtype seems to be similar, while the mixed subtype occurs remarkably less often (±10%). 15, 16, 19 CMN most commonly occurs early in infancy and over 15% of the cases are detected prenatally. 13, 15, 16, 35, 38, 39 Although CMN has been reported in 26 adult patients in literature, it remains uncertain whether these cases are real CMN's. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] 30, [65] [66] [67] [68] [69] [70] [71] [72] This clonality may be illustrative of more malignant disease, as these are the subtypes that seem to behave more aggressively.
However, no biologic studies have been performed to functionally verify this, as yet. We assume that all aforementioned genetic aberrations are somatic, since no germline genetic aberrations associated with CMN have been described. This is in line with the observation that bilateral CMN has never been reported. Besides the diagnosis of BWS in three CMN patients, no association with genetic predisposition syndromes has been reported up until now. 5, 18, 36 Occurrence of CMN in two siblings has been reported once. 73 Overall survival of CMN patients was excellent (5-year overall survival ±95%). Nevertheless, it was not 100% as suggested in earlier reports. 16, 42 It is remarkable that causes of death were treatment related in about half of the cases and most of these patients were very young (median age at diagnosis: 0 days, newborn). 2, 10, 13, 15, 17, 18, 35, 38, 39 This underscores that these infants with renal tumors deserve special attention with respect to timing and type of treatment and need a dedicated expert pediatric oncology setting. Relapses were described in only 4% of the patients. 2, 13, 15, 18, 19, 35 Virtually all relapses occurred within 12 months after diagnosis, indicating that close monitoring of all cases should be advised for at least 1 year following end of treatment. Most relapses occurred locally; however, metastatic relapses have also been reported (Supplementary Table S5 ). About 69% of the relapsed patients survived after relapse treatment consisting of individualized combinations of surgery, chemotherapy, and radiotherapy (Supplementary Table S5 ). 2, 13, 15, 18, 19, 35 Factors that seem to negatively influence outcome of CMN patients were stage III disease and cellular subtype (Supplementary Tables S4-S6) . 15 In addition to these factors, Furtwaengler et al. described age 3 months or older to be associated with the occurrence of relapse based on a univariate analysis of 50 CMN cases, which can probably be attributed to the observation that the more aggressive cellular subtype occurs most often in older patients. 15 According to the current review, patients with relapse indeed seemed to be slightly older (median age approximately 3.8 months) compared with patients without relapse (median age <1 month) (Supplementary Table S5 ). In contrast, most deceased CMN patients were relatively young (median age 0 days, newborn), mainly due to the high incidence of treatmentrelated mortality among these very young patients (Supplementary Table S5 ). However, based on the results of this review, caution with respect to chemotherapy-related toxicity is important in these young children (Supplementary Table S4 ). Targeted therapy might be an option for cases with progressive disease who do not respond to chemotherapy. In particular, Crizotinib, an ALK inhibitor that proved to be of benefit for acute lymphoblastic leukemia patients harboring the ETV6-NTRK3 transcript, resulting from the same t(12;15)(p13;q25) as described in CMN cases, could be considered as a potential compound in highly selected aggressive cases. 77 The role of radiotherapy for CMN patients is uncertain, and considering the fact that late effects of radiotherapy are suspected to be substantial in this relatively young group of patients, radiotherapy should be reserved for highly selected, aggressive, and chemotherapy-resistant cases only.
Because of the small number of relapsed CMN patients and the different treatment regimens applied in these patients, designing evidence-based treatment guidelines for relapsed CMN is not possi- Factors that seemed to be associated with occurrence of relapse were stage III disease and cellular histology. The prognostic value of t(12;15)(p13;q25) and trisomy 11, only described in cellular and mixed 
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